SEC Comment Letter for Medigus Ltd. (XYLO) (CIK 0001618500) — Nov 9, 2020

Medigus Ltd. (XYLO) (CIK 0001618500)
Date: Nov. 9, 2020 · CIK: 0001618500 · Accession: 0000000000-20-010729

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-249797

Date

November 9, 2020

Author

Not clearly detected

Form

UPLOAD

Company

Medigus Ltd. (XYLO) (CIK 0001618500)

Letter

United States securities and exchange commission logo November 9, 2020 Liron Carmel Chief Executive Officer Medigus Ltd. Tatiana Yosef 7A Industrial Park, P.O. Box 3030 Omer, 8496500, Israel Re:Medigus Ltd. Registration Statement on Form F-1 Filed November 2, 2020 File No. 333-249797 Dear Mr. Carmel: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason L. Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ron Ben-Bassat, Esq.

Show Raw Text

United States securities and exchange commission logo
November 9, 2020
Liron Carmel
Chief Executive Officer
Medigus Ltd.
Tatiana Yosef 7A Industrial Park, P.O. Box 3030
Omer, 8496500, Israel
Re:Medigus Ltd.
Registration Statement on Form F-1
Filed November 2, 2020
File No. 333-249797
Dear Mr. Carmel:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Jason L. Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Ron Ben-Bassat, Esq.

SecProbe.io